# MBrace Therapeutics

Source: https://onco.cc/companies/mbrace-therapeutics/  
OnCo record `mbrace-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MBrace Therapeutics is a United States-based biotechnology company running 2 late-stage cancer trials in prostate cancer, HR-positive / HER2-negative breast cancer and colorectal cancer.

## Summary

MBrace Therapeutics, based in San Diego, CA, the United States, is a biotechnology company. MBrace Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer, using a proprietary in vivo target-discovery platform called SPARTA. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in prostate cancer, HR-positive / HER2-negative breast cancer, colorectal cancer, non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT07145255 (Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumours), plans to enrol 150 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.mbracetrx.com

## Sources

- Official website: https://www.mbracetrx.com
- ClinicalTrials.gov: trials led by MBrace Therapeutics: https://clinicaltrials.gov/search?lead=MBrace%20Therapeutics

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- trials: [Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors](https://onco.cc/trials/nct07145255/), [Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors](https://onco.cc/trials/nct06014658/)

---
JSON: https://onco.cc/api/v1/entities/mbrace-therapeutics.json